Source | hl7.fhir.us.sirb#current:Single Institutional Review Board (sIRB) Implementation Guide (v4.0.1) |
resourceType | Questionnaire |
id | sirb-adverse-event-questionnaire-populate |
canonical | http://hl7.org/fhir/us/sirb/Questionnaire/sirb-adverse-event-questionnaire-populate |
version | 1.0.0 |
status | draft |
publisher | HL7 International - BR&R Work Group |
name | AE_Questionnaire |
title | Adverse Medical Event Questionnaire |
date | 2023-03-29T06:17:19+00:00 |
jurisdictions | us |
Usages | (none) |
Research Study
Study Title
Short title of the study, the same title listed on the Informed Consent
IRB Protocol Number
Number assigned by IRB; this number is the same as that on the Consent Form
Study Type
Select the study type, either Interventional (Clinical Trial) or Observational (Non-Interventional)
Does this protocol require an FDA exemption?
Indicator for use of FDA regulated product
Is an IND or IDE being used in this study?
Is an Investigational New Drug (IND) or Investigational Device Exemption (IDE) being used?
Select whether Investigational New Drug (IND) or Investigational Device Exemption (IDE):
IND/IDE Number
Organization/Site
Where Adverse Medical Event Occurred
Did the Adverse Medical Event occur at the lead principal investigator site? *
This question and its answer will not print on the Adverse Medical Event Form but are necessary for the form logic. Select "Yes" if the Adverse Medical Event occurred at the lead principal investigator site, the study coordinating center or other administrative unit for the overall study.
If the Adverse Medical Event occurred at one of the relying sites, select the relying site in order to pre-populate the the relying institution and relying site principal investigator details below.
This question and its answer will not print on the Adverse Medical Event Form but are necessary for the form logic. If you do not want pre-population to occur, leave this question blank and manually fill in the relying institution and relying site principal investigator details.
Name of organization/site where the event occurred
Location where Adverse Medical Event occurred. Adverse Medical Event is any untoward medical occurrence associated with a participant in research, whether or not associated with the participant's activities in the research.
Site Principal Investigator
First Name
First or given name of the principal investigator at site where Adverse Medical Event occurred
Last Name
Surname or family name
Suffix
Suffix such as Junior (Jr.), Senior (Sr.), I, II, III, IV, etc.
Degree(s)
Professional and Academic degrees of the principal investigator at site where Adverse Medical Event occurred
Phone
10-digit phone number, including area code
Principal Investigator at site where Adverse Medical Event occurred
Responsibility for Adverse Medical Event Reporting
If the Adverse Medical Event occurred at a relying site, will the lead principal investigator site be recording the Adverse Non-Medical Event? *
Select "Yes" if the Adverse Medical Event is being recorded by the lead principal investigator site, the study coordinating center or other administrative unit for the overall study.
Name of organization/site which is recording the Adverse Medical event
Location where adverse event is recorded
Primary Contact
Personnel completing the adverse medical event documentation at the lead or relying site
First Name
First or given name
Last Name
Surname or family name
Phone
10-digit phone number, including area code
Participant Information
Patient ID
Participant identifier from study case report form
Age
Birth Sex
Weight
Select pounds or kilograms
Height
Select inches, feet, centimeters, meters
Ethnicity
Race
Which Arm/Cohort/treatment group was the participant assigned to (if known)?
Patient's treatment strategy assignment, if known.
Participant dosed or received study agent
Did the participant receive the investigational agent? If answer is unknown due to blinding, select No Information.
What study agent was received:
investigational agent or placebo or blinded study
Were there any Protocol Deviations/Violations/Exceptions for this participant?
Indicator if adverse medical event occurred with protocol deviation, violation, exception
Describe the Protocol Deviations/Violations/Exceptions
Description of protocol deviations, violations, or exceptions that occurred for this participant
Adverse Medical Event Information
Submission Type
Initial: the first time that the adverse medical event is reported or Update: update on a previously reported adverse medical event
Start Date
Date adverse event started
Reported Date
Date of this report
Recorded Date
Date this adverse event was first recorded
Is the Adverse Medical Event Serious?
Event is considered serious and reportable to the FDA in the following outcomes: death, life-threatening, hospitalization, disability or permanent damage, congenital anaomaly/birth defect, need for required intervention to prevent permanent impairment or damage. See FDA Guidance: https://www.fda.gov/safety/reporting-serious-problems-fda/what-serious-adverse-event
Severity
Physician assessment using sponsor defined categories
Narrative of the Adverse Event:
Description of the SAE including chronological clinical presentation and evolution of the SAE and associated signs/symptoms. Serious Medical Event criteria are defined in the protocol.
Medical Description of Adverse Event
Diagnosis associated with adverse event. Any untoward medical occurrence associated with the use of a drug or device, whether or not considered related to the drug or device.
Is the Adverse Medical event still ongoing?
Indicator if the adverse event is still continuing or has been resolved.
Stop Date
Date that the event resolved
Was the event expected?
Indicator that Adverse Medical Event was expected or not expected.
Seriousness
Seriousness
An adverse event is considered "serious" if, in the view of either the investigator or sponsor, it results in any of the following outcomes: Death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. DFR Title 21, Part 312, Subpart B, Sec. 312.32
Other-specify
Describe other serious consequences or other medically important condition
What is the date Adverse Medical Event became serious?
Date adverse event was deemed as serious
Outcome of Adverse Medical Event
Participant's status after the adverse event
Was autopsy performed?
Indicator if participant was autopsied
Relationship of Adverse Medical Event to Study Intervention
Rationale for relationship with study intervention
Explanation for relationship between study intervention and adverse event. You may also discuss why the AE appears to be unrelated or why it is not possible to determine the relationship.
If applicable, what are possible alternate causes of the Adverse Medical Event?
Reason for possible alternative serious adverse event causes
Study Procedure-specify
Study procedure associated with SAE
Pre-existing condition-specify
Pre-existing condition associated with SAE
Underlying disease-specify
Underlying disease associated with SAE
Concomittant medication-specify
Concomitant medication associated with SAE
Other known or suspected cause-specify
Description of other causal reason associated with SAE
Action Taken
Action Taken Regarding Study Intervention
Changes to study intervention made after adverse event was detected
If study intervention was discontinued, interrupted, or dose reduced (dechallenged), did Adverse Medical Event diminish/abate?
Adverse event diminished/abated after study intervention was discontinued, interrupted, or dose reduced (dechallenged)
If study intervention was restarted (rechallenge) did AE recur?
Adverse event recurred when the study intervention was restarted
SAE Concomitant Medications, Treatments/Procedures and Tests
Did the participant receive any relevant concomitant medications in response to the SAE?
SAE Concomitant Medications
Medication Name
Name of concomitant medication given to participant in response to SAE
Indication
Indication for giving the concomitant medication to participant
Start Date
Start date for the concomitant medication given to participant
Stop Date
Stop date for the concomitant medication given to the participant
Ongoing
Is concomitant medication administration for participant ongoing?
Concomitant medication associated with SAE
Did the participant receive any treatments/procedures in response to the SAE?
Treatments/procedures administered in response to SAE
SAE Treatments/Procedures
Treatment/Procedure
Name of SAE treatment/procedure participant received
Start Date
Start date for SAE treatment/procedure participant received
Stop Date
Stop date for SAE treatment/procedure participant received
Ongoing
Is the SAE treatment/procedure for the participant ongoing
SAE treatment/procedure participant received
Did the participant receive relevant laboratory or diagnostic tests in response to the SAE?
Were any laboratory or diagnostic tests administered to the participant in response to the SAE?
SAE Laboratory or Diagnostic Tests
Lab/Diagnostic Test
Date
Result
Low Range
High Range
Comments
Laboratory or diagnostic tests obtained in response to SAE
An event that (1) is more likely than not related to study activities; and (2) represents a new risk; and (3) is unanticipated. In addition, an expected event that is occurring at a frequency or intensity greater than originally anticipated.
Optional Attachments
Describe the file that is being attached (optional)
Attachment
Attachments related to the Adverse Event Report can be included here.
Questionnaire Response ID for the parent Questionnaire Response (such as the Initiate a Study Questionnaire Response), if any
ID of the Research Study FHIR Resource associated with the study Questionnaire Responses
Produced 06 Apr 2023